Comparative Pharmacology
Head-to-head clinical analysis: LAMISIL AT versus MICONAZOLE NITRATE COMBINATION PACK.
Head-to-head clinical analysis: LAMISIL AT versus MICONAZOLE NITRATE COMBINATION PACK.
LAMISIL AT vs MICONAZOLE NITRATE COMBINATION PACK
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Terbinafine inhibits squalene epoxidase, an enzyme in the fungal ergosterol biosynthesis pathway. This leads to accumulation of squalene and depletion of ergosterol, disrupting fungal cell membrane integrity and causing cell death.
Miconazole nitrate inhibits fungal lanosterol 14α-demethylase (CYP51), disrupting ergosterol synthesis and causing fungal cell membrane damage.
Terbinafine 250 mg orally once daily for 6 weeks for fingernail onychomycosis or 12 weeks for toenail onychomycosis. Topical: 1% cream applied once daily for 1 week for tinea pedis; 1% solution applied once daily for 1 week for tinea corporis/cruris.
Intravaginally, one suppository (100 mg miconazole nitrate) once daily at bedtime for 7 days or one suppository (200 mg) once daily for 3 days, combined with topical application of miconazole nitrate cream (2%) to the vulvar area twice daily for 7 days.
None Documented
None Documented
The terminal elimination half-life is approximately 11-17 hours in healthy adults; however, it increases to about 200-400 hours in the distribution phase from tissues (e.g., skin, adipose). Steady-state is reached after 10-14 days of oral dosing.
Terminal elimination half-life is approximately 20-25 hours, but can be prolonged to 30-40 hours in patients with hepatic impairment.
Terbinafine is extensively metabolized in the liver; approximately 80% of a dose is excreted in urine as metabolites, and 20% in feces. Less than 1% is excreted unchanged in urine.
Primarily fecal (biliary) as unchanged drug and metabolites (~50-60%); renal excretion accounts for <20% of the dose, mostly as inactive metabolites.
Category C
Category A/B
Antifungal
Antifungal